IDH1 and acute myeloid leukemia: As ivosidenib or 5-azacytidine pre-treatment did not abrogate the beneficial effect of dasatinib in IDH1-mut AML cells and as the combination of dasatinib and ivosidenib appeared to be beneficial, our data suggest dasatinib as novel treatment option, also in combinations, for patients with IDH1 p.R132H mutant AML.